Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers-论文-万方医学网

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

导出原文传递

翻译打印收藏纠错

作者： Odintsov, Igor ^[1] ; Mattar, Marissa S. ^[2] ; Lui, Allan J. W. ^[3] ; Offin, Michael ^[4] ; Kurzatkowski, Christopher ; Delasos, Lukas ; Khodos, Inna ; Asher, Marina ; Daly, Robert M. ; Rekhtman, Natasha ; de Stanchina, Elisa ; Ganji, Gopinath ; Ladanyi, Marc ; Somwar, Romel

作者单位： Dept Pathol,Mem Sloan Kettering Canc Ctr ^[1] Dept Pharmacol,Mem Sloan Kettering Canc Ctr ^[2] Dept Med,Mem Sloan Kettering Canc Ctr ^[3] Res & Dev,GlaxoSmithKline ^[4]

关键词 NRG1 fusion HER3 antibody Lung adenocarci-noma GSK2849330 GAMMA-HEREGULIN MSK-IMPACT CELL-LINE GROWTH

发布时间 2022-10-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除